title: Neonatal drug withdrawal.
abstract: Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.
authors.forename: Mark L
authors.initials: ML
authors.lastname: Hudak
authors.forename: Rosemarie C
authors.initials: RC
authors.lastname: Tan
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D013287:Illicit Drugs / Q000009:adverse effects*; D007231:Infant, Newborn; D009357:Neonatal Abstinence Syndrome / Q000175:diagnosis / Q000628:therapy*; D011247:Pregnancy; D015813:Substance Abuse Detection
chemical_list: D000701:Analgesics, Opioid; D006993:Hypnotics and Sedatives; D013287:Illicit Drugs; D001569:Benzodiazepines